How do you approach valuing an AI company that has explosive revenue growth, heavy compute costs, and no profits — and why can revenue multiples from peers mislead?
An advanced Valuation question — expect it in final rounds and case-heavy interviews (IB, PE, Big-4 Transaction Services).
THE SHORT ANSWER
First understand unit economics, because AI businesses differ structurally from classic SaaS: inference compute scales with usage, so gross margins can be 50-60% rather than 80%+, and each revenue dollar may carry ongoing model-training capex. Revenue multiples borrowed from SaaS peers implicitly assume SaaS margins and retention — applying them to lower-margin, less-sticky AI revenue overprices the asset. A defensible approach: build a driver-based DCF with explicit assumptions on gross margin evolution (compute cost curves, model efficiency gains), retention/NRR evidence, and competition-driven pricing decay; triangulate with growth-adjusted and margin-adjusted multiples (e.g. multiple per point of gross margin, rule-of-X); and stress-test moat assumptions — many 'AI companies' are thin wrappers over foundation models with little pricing power. Also separate revenue quality: committed enterprise contracts versus experimentation budgets that churn when pilots end. State the scenario spread honestly; a single point estimate for such an asset is false precision.
WHAT INTERVIEWERS LISTEN FOR
- ✓inference compute makes gross margins structurally lower
- ✓SaaS multiples embed margin/retention assumptions that may not hold
- ✓driver-based DCF with compute-cost and pricing-decay assumptions
- ✓margin-adjusted multiple triangulation
- ✓revenue quality: committed contracts vs. pilot budgets
COMMON MISTAKES
- ✗applying SaaS peer multiples without margin adjustment
- ✗treating pilot revenue as recurring
You've seen the model answer. Now get graded on yours.
In the interview you won't have this page — you deliver your version on a clock. Practice this and 1,000+ questions with AI feedback on every answer.
RELATED QUESTIONS
- How do you value a company with no revenue?
- Explain accretion/dilution analysis.
- How would you value a company in a cyclical industry?
- What is the most appropriate valuation methodology for a company with significant intangible assets but no current revenue, such as a biotech startup in the pre-clinical stage?
- When calculating WACC for a company with multiple divisions in different countries, what is the correct approach?
- How does a private equity buyer use an LBO to set the maximum price it can pay, and why is this a valuation floor?